Skip to main content

Influenza Vaccines Market Size to Reach USD 7.34 Billion with 7.7% CAGR; Increasing Demand for Effective Flu Vaccines to Aid Market Expansion: Fortune Business Insights™

Written by Customer Service on . Posted in Mergers And Acquisitions.

Pune, Oct. 20, 2020 (GLOBE NEWSWIRE) — The global influenza vaccines market size is slated to reach USD 7.34 billion by 2026, exhibiting a CAGR of 7.7% during the forecast period. Increasing prevalence of influenza worldwide will be the major driving force behind the growth of this market.According to the World Health Organization (WHO), around 3 to 5 million cases of influenza-based diseases are reported annually across the globe. This has spurred governments to take proactive measures to contain the spread of this deadly disease. Many governments carry out extensive vaccination drives before the flu season begins to immunize people from contracting any such infections, bolstering the seasonal influenza vaccines market demand.In addition to market value, the report provides the following:An exhaustive research into the different segments to comprehensively understand the market;A careful study of the industry trends that will shape the size, share, and overall growth of the market; andA detailed assessment of the various factors, future prospects, and regional and competitive dynamics influencing the market.
Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/influenza-vaccine-market-101896
Initiation of Government-backed Immunization Programs to Foster Greater DemandGovernments all around the world are increasingly focusing on initiating large-scale immunization drives to tackle influenza and related diseases, which is benefiting the flu vaccine market. These initiatives are receiving active support from international organizations such as the WHO.More importantly, these bodies are increasing their surveillance capacities to contain the spread of the disease and taking all measures necessary to prevent the outbreak of an epidemic. Many organizations, such as the Bill and Melinda Gates Foundation, Centers for Disease Control and Prevention (CDC), and WHO Global Influenza Surveillance and Response System (GISRS), are also facilitating research through increased funding for the development of up-to-date vaccines.
To know more about the long-term and short-terms impacts of COVID-19 on this market, please click on this link: https://www.fortunebusinessinsights.com/industry-reports/influenza-vaccine-market-101896
North America to Occupy a Commanding Position; Asia-Pacific to Register Robust GrowthHaving generated a revenue of USD 1.98 billion in 2018, North America is expected to dominate the influenza vaccines market share primarily owing to the utilization of advanced manufacturing systems and processes for vaccines. Besides this, rising incidence of influenza, well-funded vaccine research programs, and presence of big companies will further fuel the market in this region.Asia-Pacific will boast the highest growth rate among regions on account of fast-increasing population along with active government support for healthcare research will raise the demand for effective vaccines in the region. Lastly, increasing immunization rate, coupled with high awareness regarding vaccination, will drive the market in Europe.  
Quick Buy –  Influenza Vaccine Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/101896
Key Industry Developments:November 2019: Sanofi received clearance for its Fluzone® High-Dose Quadrivalent from the US Food and Drug Administration (FDA). Containing an additional Influenza B strain, the drug is designed and aimed at treating adults at and over the age of 65.January 2019: The European Commission green lit Seqirus’s FLUCELVAX® TETRA for marketing in Europe. This is a cell-based quadrivalent influenza vaccine, the first of its kind to be marketed in Europe, which is to be used on people aged 9 years and above.
Top Players Profiled in the Influenza Vaccines Market:•          AstraZeneca•          F. Hoffmann-La Roche Ltd•          Sanofi•          GlaxoSmithKline plc.•          Sinovac Biotech Ltd•          CSL Limited•          Emergent BioSolutions Inc.•          BioDiem
Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/influenza-vaccine-market-101896
Table of Contents:IntroductionResearch ScopeMarket SegmentationResearch MethodologyDefinitions and AssumptionsExecutive SummaryMarket DynamicsMarket DriversMarket RestraintsMarket OpportunitiesKey InsightsNew Product LaunchPipeline AnalysisPrevalence of Influenza- For Key Countries, 2018Key Industry Developments – Mergers, Acquisitions, and Partnerships
TOC Continued….!
Get your Customized Research Report: https://www.fortunebusinessinsights.com/enquiry/customization/influenza-vaccine-market-101896
SECONDARY DATA SOURCES THAT WE REFER TO:Annual reports, investor presentation, SEC filings, and press releases of companies operating in the marketStudies published by relevant associations MedTech Europe; American College of Radiology; Cancer Council Australia; Japan Hospital Association, etc.), government sources (Centers for Disease Control & Prevention, Ministry of Health, Labour & Welfare, Japan; National Health Service, England, etc.), international organizations (World Health Organization, The Organization for Economic Co-operation and Development, Eurostat, etc.), and articles published by Research Gate, NCBI, etc.Website, reports, and press releases of end user facilities – Hospitals, Ambulatory Surgery Centres, ClinicsIndustry journals and paid databasesSECONDARY RESEARCH IS CONDUCTED TO DERIVE THE FOLLOWING INFORMATION:Details such as revenues, market share, strategies, growth rate, product & their pricing by region/country for all major companiesDetails in relation to prevalence, incidence, patient numbers, distribution of patients, average price of treatment, etc.Number of end user facilities by region/country and average annual spending or procurement of devices by type of end user facilityNumber of procedures and average price of proceduresReplacement rate and pricing of capital equipmentMarket dynamics in relation to the market under focus – Drivers, restraints, trends, and opportunitiesMarket & technological trends, new product developments, product pipeline.
Have a Look at Related Reports:Vaccines Market Share & Industry Analysis, By Type (Recombinant/Conjugate/Subunit, Inactivated, Live Attenuated and Toxoid), By Route of Administration (Parenteral and Oral), By Disease Indication (Viral Diseases and Bacterial Diseases), By Age Group (Pediatric and Adults), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers and Others) and Region Forecast, 2019-2026Germany Pneumococcal Vaccines Market Share & Industry Analysis, By Product Type (PCV10, PCV13, and PPSV23), By End User (Hospitals, Clinics, and Others) and Region Forecast, 2019-2026Human Papillomavirus (HPV) Vaccines Market Share & Industry Analysis, By Type (Bivalent and Polyvalent), By Disease Indication (HPV Associated Cancer and Genital Warts), By Distribution Channel (Hospital & Retail Pharmacies, Government Suppliers, and Others) and Geography Forecast, 2019-2026Veterinary/Animal Vaccines Market Share & Industry Analysis, By Product (Inactivated, Live Attenuated, Recombinant, Others), By Animal (Companion, Livestock), By Route of Administration (Oral, Parenteral, Others), By Distribution Channel (Veterinary Hospitals, Veterinary Clinics, Pharmacies & Drug Stores, Others) and Regional Forecast, 2019-2026
About Us:Fortune Business Insights™ offers expert corporate analysis and accurate data, helping organizations of all sizes make timely decisions. We tailor innovative solutions for our clients, assisting them to address challenges distinct to their businesses. Our goal is to empower our clients with holistic market intelligence, giving a granular overview of the market they are operating in.Our reports contain a unique mix of tangible insights and qualitative analysis to help companies achieve sustainable growth. Our team of experienced analysts and consultants use industry-leading research tools and techniques to compile comprehensive market studies, interspersed with relevant data.At Fortune Business Insights™ we aim at highlighting the most lucrative growth opportunities for our clients. We, therefore, offer recommendations, making it easier for them to navigate through technological and market-related changes. Our consulting services are designed to help organizations identify hidden opportunities and understand prevailing competitive challenges.
Contact Us:Fortune Business Insights™ Pvt. Ltd.
308, Supreme Headquarters,
Survey No. 36, Baner,
Pune-Bangalore Highway,
Pune – 411045, Maharashtra, India.Phone:
US :+1 424 253 0390
UK : +44 2071 939123
APAC : +91 744 740 1245
Email: sales@fortunebusinessinsights.com
Fortune Business Insights™
LinkedIn | Twitter | Blogs
Press Release: https://www.fortunebusinessinsights.com/press-release/influenza-vaccines-market-9472

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.